Gynecologic Oncology - Endometrial Cancer | |
|---|---|
| Study Name | Principal Investigator |
| MK7902-001 – A Multicenter, Open-label, Randomized Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer. Hypothesis is that combination therapy leads to improved progression-free survival. Read more. |
Sharyn Lewin, MD |
| MK3475-775 – A Phase 3 Randomized, Open-label, Study of Pembrolizumab (MK-3475) Plus Levantinib versus Chemotherapy for First-Line Treatment of Advanced or Recurrent Endometrial Carcinoma. Hypothesis is that the combination for pembrolizumab plus Levantinib is superior to chemotherapy with respect to progression-free survival. Read more. |
Sharyn Lewin, MD |
| GOG-3039 – A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, |
Sharyn Lewin, MD |
| AZ DUO-E – A Randomized, Multicentre, Double-blind, Placebo-controlled, Phase III Study of |
Maria Schiavone, MD |
Gynecologic Oncology - Ovarian Cancer | |
| Study Name | Principal Investigator |
| FIRST – A Randomized, double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer. Hypothesis is that TSR-042 and Niraparib produces a deeper response and prolonged progression-free survival. Read more. |
Sharyn Lewin, MD |
| MK7339-001 – A randomized phase 3, double-blind study of chemotherapy with or without Pembrolizumab followed by maintenance with Olaparib or placebo for the first-line treatment of BRCA non-mutated advanced epithelial ovarian cancer. Read more. |
Maria Schiavone, MD |
| QPT-ORE-005 – A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Read more. |
Sharyn Lewin, MD |
| LAE002INT2001 – An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cance Read more. |
Maria Schiavone, MD |
| IMGN853-0416 – A randomized, open-label, phase 3 study of Mirvetuximab Soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression (MIRASOL) Read more. |
Sharyn Lewin, MD |
| IMGN853-0417 – A phase 3, single arm study of Mirvetuximab Soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha expression (SORAYA) Read more. |
Sharyn Lewin, MD |
| AVB500-OC-004 – A phase 3, randomized, double-blind, adaptive, placebo/Paclitaxel-controlled study of AVB-S6-500 in combination with Paclitaxel in patients with platinum-resistant recurrent ovarian cancer (ARAVIVE) Read more. |
Sharyn Lewin, MD |
| IMGN853-0419 – A Phase 2, Single Arm Study of Mirvetuximab Sorvtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (PICCOLO). Read more. |
Sharyn Lewin, MD |
| IMGN853-0420 – A Multicenter, Open-label, Phase 2 Study of Carboplatin plus Mirvetuximab Soravtansine followed by Mirvetuximab Soravtansine continuation in Folate Receptor-Alpha Positive, Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following One Prior Line of Platinum-Based Chemotherapy. For more information about this study and to inquire about eligibility, please contact the Oncology Research Program at 201-530-7934. Read more. |
Sharyn Lewin, MD |
